ENTO Stock: Entero Therapeutics, Inc. Stock Price, Analysis & Insights
Get live ento stock price $3.15, comprehensive Entero Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time ento stock data and investment insights.
Company Overview
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Company Information
- CEO
- Richard Joel Paolone
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
Contact Information
- Website
- https://www.firstwavebio.com
- Address
- 777 Yamato Road
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 15.01M market capitalization
- Trading Volume: 612.61K shares traded today
- Price Range: 52-week range of $0.92 - $3.29
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Entero Therapeutics, Inc.
Entero Therapeutics, Inc. (ENTO) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 15.01M, the company represents a significant player in its market. The stock is currently trading at $3.15 with a positivedaily change of 36.96%.
The company's 2 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.26, beta of 0.89, and 52-week price range from $0.92 to $3.29when evaluating investment opportunities.
Why Invest in Entero Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Richard Joel Paolone
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.